Compare SHAZ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAZ | ANAB |
|---|---|---|
| Founded | 2024 | 2005 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | SHAZ | ANAB |
|---|---|---|
| Price | $66.88 | $63.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $46.67 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.3M | 556.4K |
| Earning Date | 06-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $8,711.27 | N/A |
| Revenue Next Year | $587.87 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $16.55 | $17.11 |
| 52 Week High | $97.48 | $73.30 |
| Indicator | SHAZ | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 57.92 |
| Support Level | $52.07 | $52.32 |
| Resistance Level | $92.21 | $67.69 |
| Average True Range (ATR) | 10.70 | 3.22 |
| MACD | -1.60 | 1.13 |
| Stochastic Oscillator | 31.79 | 60.92 |
SharonAI Holdings Inc is a neocloud operator, purpose-built to power the next generation of artificial intelligence (AI) and high-performance computing (HPC). The Company's infrastructure is architected from the ground up to meet the specific, intensive, and complex demands of modern AI training and inference workloads, machine learning, and Generative AI. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, and SHARON AI Studio. The company's products are: SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, and Machine Learning & Infrastructure. The Company operates in one operating segment, High Performance Compute Services (HPC).
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).